Samsung and Bottneuro partnered when Bottneuro AG spun off from the University of Basel in 2021. Although no satisfactory treatment method capable of stopping Alzheimer's disease or other forms of dementia exists, Bottneuro uses patient-specific 3D MRI and PET data to identify areas of the brain that are particularly affected. It then uses a 3D-printed Miamind neurostimulator to electrically stimulate those areas.
The Galaxy Tab S8+ Enterprise Edition and Knox simplify the process
The Miamind neurostimulator is connected to a Galaxy Tab S8+ Enterprise Edition. The tablet controls the neurostimulator, transmits therapy data, and simplifies operations through a graphic interface. The tablet, along with the 3D-printed neurostimulator, is provided to patients during treatment.
The whole process is supported further by the Samsung Knox suite, including Knox Manage, E-FOTA, KAI, KSP, and Knox Configure. Through Knox, Bottneuro can automatically pre-configure the Galaxy Tab S8+ Enterprise Edition tablets to meet the needs of using the device with the 3D-printed neurostimulator.
“We are pleased to offer Bottneuro a reliable, safe, and simple solution with Knox and to support their novel therapy approach,” said Daniele Casella, Head of MX B2B Mobile at Samsung Switzerland. Bottneuro AG's therapy solution is not yet commercially available, but the therapy's effectiveness will be tested in clinical studies this year.
